IKT - Inhibikase begins mid-stage trial of IKT-148009 for Parkinson's disease following FDA review

Inhibikase (NASDAQ:IKT) said on Monday it was starting its Phase 2a study testing IkT-148009 to treat Parkinson's disease, following review of the study protocol and Phase 1/1b data by the U.S. Food and Drug Administration. The company said the Phase 2a trial, dubbed 201, was open for enrollment and it expect to dose first patient in Q2. IKT's Phase 1/1b '101' study was terminated early, the company said. The trial demonstrated favorable safety, tolerability, and pharmacokinetic profile in single doses up to 325 mg and multiple doses up to 100 mg. The mid-stage trial will measure the safety of the drug and hierarchy of Parkinson's-related disease assessments in the brain and gut as secondary or exploratory endpoints. "Inhibikase expects that at least 7 of 40 total sites will be open by the end of the second quarter this year," the company said. (IKT) rose ~1% before the bell.

For further details see:

Inhibikase begins mid-stage trial of IKT-148009 for Parkinson's disease following FDA review